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Abstract Research in the last decade has shown that
hematopoietic stem cells (HSCs) interact with and are
modulated by a complex multicellular microenvironment
in the bone marrow, which includes both the HSC progeny
and multiple non-hematopoietic cell types. Intense work is
gradually throwing light on the composition of the HSC
niche and the molecular cues exchanged between its
components, which has implications for HSC production,
maintenance and expansion. In addition, it has become
apparent that bidirectional interactions between leukemic
cells and their niche play a previously unrecognized role in
the initiation and development of hematological malig-
nancies. Consequently, targeting of the malignant niche
holds considerable promise for more specific antileukemic
therapies. Here we summarize the latest insights into HSC
niche biology and recent work showing multiple connec-
tions between hematological malignancy and alterations in
the bone marrow microenvironment.
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Abbreviations
HSC Hematopoietic stem cell
HSPC Hematopoietic stem cells and progenitors
MPP Multipotent progenitors
LSC Leukemia stem cell
MSC Mesenchymal stem cell
AML Acute myeloid leukemia
ALL Acute lymphoblastic leukemia
MPN Myeloproliferative neoplasm
CML Chronic myeloid leukemia
Introduction
The concept of stem cell niche, in the context of the
hematopoietic system, implies that the behavior of
hematopoietic stem cells (HSCs) is to a great extent
modulated by their microenvironment in the bone marrow.
Underlying the interest in the study of the HSC niche are
two practical hypotheses: (1) precise characterization of the
cell populations and factors produced by them, responsible
for HSC maintenance in vivo, holds the clue for HSC
expansion ex vivo; (2) knowledge of how the niche is
modified in hematological diseases (such as dysplasias and
leukemias) might allow selective therapeutic targeting that
eliminates abnormal HSCs while restoring normal hema-
topoiesis. However, the complex cellular composition of
the BM cavity, the multiple anatomical and functional
interactions between its components—not yet fully char-
acterized—and its apparent lack of physical
compartmentalization into discrete, organized structures
analogous to stem cell niches described in other tissues
have complicated the cellular and molecular dissection of
the HSC niche. As a consequence, significant progress in
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the two above mentioned directions has only begun to
occur in very recent years. In this review, we discuss the
most recent insights into the biology of HSCs and their
niche, some of the technical difficulties that have been
encountered, and recent work revealing the relationship
between hematological disease and abnormalities of the
HSC niche.
HSCs: current dogmas and evolving concepts
Our idea of the HSC has traditionally been dominated by a
number of concepts:
1. A static, long-term HSC with fixed specific features
(including a characteristic immunophenotype, quies-
cent state, self-renewing properties), ultimately
responsible for maintaining hematopoiesis through
life.
2. A convenient, straightforward, but simplistic model of
progenitor hierarchy, in which a homogeneous popu-
lation of HSC differentiates into progenitors and
subsequently mature lineages along bifurcating, non-
reversible, non-overlapping paths.
3. A rigid idea of a ‘‘HSC niche’’, in which—by analogy
with certain non-hematopoietic tissues—the HSC is
postulated to ‘‘reside’’ more or less statically in
discrete anatomical microenvironments, the exact
identity of which has remained elusive. The growing
amount and complexity of information concerning the
influence of many other bone marrow cells on HSC
behavior has lead to postulate the existence of
functionally different HSC niches, which is still not
sufficiently substantiated by the experimental data
available [1].
In the light of the results reported over the last few
years, this image is gradually evolving toward a much
more dynamic model:
(A) Heterogeneity in HSC proliferation and self-re-
newal Analyses of the mouse and human HSC
compartments have revealed variability in the cell cycle
status and self-renewal capacity of individual HSCs. In the
mouse, populations of ‘‘dormant’’ and ‘‘activated’’ HSCs
have been identified, which are to some extent intercon-
vertible. Dormant HSCs divide at very slow rates in
homeostasis (every 145 days), exhibit the highest self-re-
newal and multilineage repopulation activity and, although
transiently activated by bone marrow injury or by granu-
locyte colony-stimulating factor (G-CSF), they revert to
quiescence after reestablishment of homeostasis in a non-
stochastic fashion [2]. HSCs switch from a proliferative to
a quiescent status 3–4 weeks after birth [3] and are
believed to undergo a similar transition after ex vivo
manipulation requiring cytokine stimulation (e.g., retrovi-
ral transfer). Human HSCs also show heterogeneous self-
renewal ability in xenotransplantation assays, with a lim-
ited number of clones providing long-term reconstitution
and others exhibiting fluctuating contributions to hemato-
poiesis [4].
These observations may suggest that HSC fate is ini-
tially unpredictable and occurs stochastically, but it may
also in part reflect limitations in the methods currently used
for the isolation and functional analysis of HSCs. Thus,
despite significant improvements, the best combinations of
phenotypic markers in the mouse reach about 50 % purity,
measured by competitive transplant assays [1, 5], or
exclude a substantial fraction of HSCs [6]. Recently, based
on combined transcriptomic and functional analysis at the
single cell level, Wilson et al. [7] have proposed an
improved sorting strategy that increases purity up to 67 %.
Strategies to isolate human HSCs still lag behind in terms
of purity, and their functional validation is complicated by
the relatively low engraftment frequency of xenotransplant
assays. Only 9.5 % of lin- CD34? CD38- CD45A-
Thy1? CD49f? cells exhibit long-term repopulating
activity in intrafemorally injected NOD-scid-IL2Rgc-/-
mice, and a small fraction of HSCs is apparently Thy1- [8].
Therefore, even after selecting cell populations with the
best combinations of markers available, studies at non-
clonal levels must take into account that these cell popu-
lations are not pure but only enriched in the expected
HSCs.
(B) Heterogeneity in multilineage differentiation
capacity of HSCs Retrospective analyses of single cells or
clonal transplant experiments have demonstrated different
kinetics and patterns of multilineage haematopoietic
reconstitution derived from individual murine HSCs. Up to
16 distinct differentiation patterns were identified, based on
their relative lymphomyeloid output and kinetics [9–11]. In
the absence of markers that would allow their prospective
isolation, it remains unknown whether each HSC was
deterministically imprinted with a differentiation program,
whether cell fate choice occurred stochastically or whether
it was imposed by the microenvironment upon transplan-
tation. Moreover, there was variability in the stability or
‘‘memory’’ of such program: while sometimes the differ-
entiation pattern was preserved upon serial
transplantations, in other cases a switch was observed. In
this regard, there is some evidence that spontaneous,
stochastic gene expression ‘‘noise’’ in HSCs may affect
lineage choice [12].
(C) Contribution of hematopoietic progenitor cells to
hematopoiesis Traditionally, transplantation assays have
served as the gold standard to assess HSC function. Under
transplantation conditions, long-term reconstitution ability
seems to be restricted to a small number of primitive LT-
A. Sa´nchez-Aguilera, S. Me´ndez-Ferrer
123
HSCs, and hematopoiesis is typically oligoclonal. How-
ever, recent studies using genetic labeling and clonal
tracing of HSC have revealed a very different situation
during adult steady-state hematopoiesis, in which blood
cell production is highly polyclonal and predominantly
maintained by ‘‘short-term HSCs’’ or progenitors down-
stream of LT-HSCs, with strong myeloid bias [13, 14].
Moreover, within myeloid progenitors, multiple subgroups
with heterogeneous differentiation patterns have been
identified [15].
Notwithstanding technical limitations, these data sug-
gest that, contrasting the concept of stable and discrete
HSPC populations, a more dynamic situation may exist in
which there is some degree of plasticity in the proliferation
and differentiation capacity of HSCs and their progeny. It
is still unclear to what extent this is regulated through
dynamic interactions with the microenvironment or via
stochastic, cell-autonomous fluctuations in the HSC
transcriptome.
The HSC niches: structurally organized
or stochastic/variable entity?
The growing amount of information concerning the HSC
niche in recent years has paradoxically led to a situation of
relative confusion, in which virtually every non-he-
matopoietic cell type in the bone marrow (osteoblasts,
osteocytes, endothelial cells, stromal reticular cells, peri-
cytes including MSC-like cells, adipocytes, non-myelinated
Schwann cells, sympathetic neurons) plus several mature
hematopoietic populations (macrophages, neutrophils,
osteoclasts, megakaryocytes, Treg cells) have been proposed
as niche components and/or critical regulators of HSC
function (Fig. 1 left; Table 1). Here it would be worth
attempting a clarification between those effects likely due to
direct interaction between HSCs and anatomically close
cellular components (thus properly called ‘‘niche’’ cells) and
non-specific effects arising from the disruption of a very
interconnected, complex multicellular system like the bone
marrow, which requires a finely regulated homeostatic bal-
ance. Altering any major population in the bone, or the bone
metabolism itself, will likely have indirect consequences on
most bone marrow-resident cells due to profound structural
and biochemical changes; on the other hand, experimental
disruption of mature hematopoietic cells is bound to elicit a
compensatory response in primitive HSPCs. However, nei-
ther of these are necessarily indicative of a ‘‘niche’’ function,
and experimental dissection of direct and indirect effects
may not be trivial.
One of the most controversial aspects in the last decade
has been the role of osteolineage cells as HSC niche
components. Although this was the first population in the
BM linked to HSC regulation, and a fraction of HSCs tend
to home to the vicinity of osteoblasts, some of the effects
observed may be indirect, and deletion of key HSC-sup-
porting factors from osteoblasts seems to have little effect
on HSCs ([16, 17]; reviewed in [18]). One caveat of some
of these studies is the difficulty to discriminate in vivo
between osteoblasts/osteoprogenitors and more primitive
mesenchymal progenitors, because genetic drivers rou-
tinely used to mark these populations show overlapping
expression patterns (reviewed in [19]). Recent research
suggests that the periosteal region may support more
committed progenitors, particularly of the lymphoid lin-
eages (see below).
Non-myelinating
Schwann cellsMesenchymal stromal cells
(including various subsets of 
mesenchymal / osteoblastic progenitors, 
pericytes and CAR cells)
Sympathetic
neuron
Mature myeloid progeny
(megakaryocytes, macrophages, neutrophils)
HSC
Lymphoid progenitors
Osteoblasts
Blood vessels
(sinusoids,
arterioles)
Endothelial
cells
TGFβ
Cxcl12,
SCF
indirect
factors
indirect
factors?
TGFβ
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mesenchymal stromal cells / 
osteoprogenitors
Loss of sympathetic fibers
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IL-1β, IL-6
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Fig. 1 Overview of the main components of the HSC niche and their
alterations in leukemia. Simplified schematic of the normal HSC
niche (left) and its alterations in the context of malignancy. The
diagram does not attempt to comprehensively include every cell
population and molecule implicated in HSC regulation but to
illustrate some of the best characterized candidate niche cells and
factors, particularly those that have been found altered in leukemias.
The right panel summarizes niche abnormalities observed in various
experimental models representing different leukemia types. There-
fore, it does not intend to propose a general model nor to describe the
pathophysiology of any particular malignancy. HSC hematopoietic
stem cell, LSC leukemia stem/initiating cell
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Table 1 Summary of different cell types and their role in the normal and leukemic HSC niches
Cell type Factors
produced
Role in the normal HSC niche Role in the leukemic niche
Nonhematopoietic
cells
Osteoprogenitors/
osteoblastsa
Cxcl12,
Angpt1,
DLL4
Initial—but controversial—evidence
implicating osteoblasts in HSC
regulation (probably indirect) [18];
HSC home near, but rarely adjacent
to, osteoblasts; possible role in the
formation of the HSC niche; support
of early lymphoid progenitors in the
BM [29–31]
Diverse genetic manipulations of
osteolineage cells (Dicer1, Ctsb,
Sbds, Ctnnb1) induce preleukemic
conditions [55, 60, 61]; transplanted
human ALL/AML cells home near
the endosteum [66–69]; CML cells
stimulate production of abnormal
osteoblasts that support LSC [73]
Osteocytes G-CSF
(indirect)
Regulation of osteoblast function via
cellular processes and gap junctions
[20–23]
Sympathetic neurons Noradrenaline Regulate circadian egress of HSC and
expression of HSC maintenance
genes in MSC [47]
Production of IL-1b by JAK2V617F?
MPN cells leads to neuroglial damage
in the BM, with loss of sympathetic
fibers and associated Schwann cells;
this, in turn, compromises survival of
Nes? cells [76]
Nonmyelinating
Schwann cellsa
Active TGF-b Maintenance of HSC quiescence [24]
Endothelial cellsa Cxcl12, Scf,
Angpt1,
Notch ligands
HSC maintenance/retention; deletion of
Cxcl12 or Scf from Tie2?
endothelial cells depletes HSC
[1, 5, 16, 17]
Increased numbers of endothelial cells
and angiogenesis in mice and patients
with AML
Arteriolar endothelium
and pericytesa
Proposed role in the maintenance of
HSC quiescence [25], recently
questioned
Proposed problem of MSC
differentiation contributing to
reduced number of osteoblasts in
AML
CAR cellsa Cxcl12 Heterogeneous stromal cells with high
Cxcl12 expression; Cxcl12 deletion
leads to HSC depletion [81]
Nes? cellsa Cxcl12, Scf,
Angpt1…
Promote homing and maintenance of
HSC; mediate sympathetic circadian
signaling to HSC [82]
Apoptosis of Nes? cells in JAK2V617F?
MPN accelerates disease progression
[76]
Lepr? perivascular
stromal cells
Cxcl12, Scf HSC maintenance/retention; deletion of
Cxcl12 or Scf from Lepr?
perivascular cells depletes HSCs
[16, 17]
Adipocytes Adiponectin,
TNF-a
Negative regulators of homeostatic and
post-transplant hematopoiesis [83]
Hematopoietic
cells
Monocytes/macrophagesa Vcam1, PGE2;
regulate
Cxcl12 on
stromal cells
Promote retention of HSC and
progenitors in the BM; required for
HSC maintenance and erythropoiesis
in response to stress [32–36]
Altered secretory pattern of leukemic
myeloid cells in CML/MPN
(including proinflammatory cytokines
such as IL-1b and IL-6) creates
abnormal niches that favors
malignant over normal
hematopoiesis; IL-6 also drives
myeloid differentiation of MPP
[73–76]
Neutrophils (Indirect,
mediated by
macrophages)
Clearance of aged neutrophils attracts
macrophages; decreases CAR cells
and Cxcl12 levels [47]
Osteoclasts Controversial; possible role in HSPC
mobilization [37–40]
Megakaryocytesa TGF-b1, Cxcl4,
PDGF-BB
Maintain HSC quiescence [41–44];
promote niche remodeling and
osteoblast expansion after irradiation
[45]
Treg cellsa IL-10 Locate near HSC at endosteum and
protect them from immune clearance,
suppressing T-cell activation [48]
a Physical proximity to an HSC-enriched population in the bone marrow was directly demonstrated. Mesenchymal cell populations currently
classified under different nomenclature (osteoprogenitors, Nes? cells, Lepr? cells, CAR cells) may partially or substantially overlap; conversely, a
given cell type (e.g., endothelial) may comprise different populations depending on the choice of genetic drivers or surface markers in each particular
study
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Osteocytes have been reported to regulate hematopoiesis
through both secretion [20] and responsiveness [21] to
G-CSF. However, due to their anatomical location, effects
on HSCs could be indirect. An emerging concept is that
osteocytes communicate with endosteal osteoblasts through
dendritic processes and may regulate their function via gap
junctions [22, 23]. Mice deficient for Gsa in osteocytes
exhibit loss of trabecular and cortical bone associated with
expansion of myeloid cells, an effect partly mediated by
G-CSF production by osteocytes [20]. In turn, osteocytes
were shown to rapidly respond to G-CSF by downregu-
lating bone-specific genes and undergoing morphological
changes, with loss of the cellular processes that connect
them with osteoblasts [21]. In this study, ablation or dis-
ruption of the osteocyte network preceded loss of
osteoblasts, prevented G-CSF-induced HSPC mobilization,
increased bone marrow Cxcl12 levels and induced HSC
quiescence.
Non-myelinating Schwann cells have been reported to
contribute to maintain HSCs in a quiescent state through
TGF-b production [24]. Arterioles preferentially located
near the bone surface were also found to provide niches for
quiescent HSCs [25]. However, a recent study has found
most quiescent and non-quiescent HSCs far from bone and
arterioles and close to sinusoidal vessels, which are much
more abundant and widely distributed in the BM [1].
Whereas most HSCs might reside in this larger region of
the BM, it remains possible that a different microenvi-
ronment in the endosteum maintains a different HSC state/
population. It must be kept in mind that studies reporting
HSC localization in the BM have employed different
marker combinations to identify non-identical HSC-en-
riched cellular pools, which may account for some of the
discrepancies. Thus, the latter report utilized the newly
described reporter a-catulin [1], while the arteriole study
used SLAM markers [25].
One of the puzzling aspects when trying to extrapolate
the concept of stem cell niche (as derived from evidence in
solid tissues) to the bone marrow is the apparent absence of
compartmentalization of the latter into discrete structures
sheltering the HSC. The existence of such compartments,
however, has been speculated. Structures termed ‘‘hemo-
spheres’’ (containing mesenchymal, endothelial and
hematopoietic cells) were shown to be enriched in
CD150? CD58- HSCs and seemed to represent sites of
clonal hematopoietic cell proliferation. Hemospheres were
found in sinusoidal vessels at the periphery of the BM
cavity, associated with NG2? Pdgfrb? Nestin? CD146?
pericytes, and required expression of VEGFR2 in the
endothelium [26]. A recent study using high-resolution live
imaging has suggested that this type of structures may not
be permanent but dynamic. In zebrafish fetal hematopoietic
tissue, the perivascular niche remodels upon arrival of a
HSPC, forming a pocket-like compartment in which a
group of endothelial cells surround an HSPC attached to a
mesenchymal stromal cell. This structure seems to deter-
mine the polarity of HSC division [27]. Additional
intravital imaging studies have revealed that HSCs also
interact dynamically within the niche and, while their
motility is restricted to small oscillations under resting
conditions, they become more migratory upon activation
(e.g., through acute infection), resulting in their contact
with larger areas of the BM [28].
Recent evidence suggests that diverse bone marrow
locations may function as niches for different hematopoi-
etic progenitors. The evidence is stronger for
lymphopoietic niches, which have been associated with IL-
7-enriched bone regions [29, 30]. Also, specific deletion of
Cxcl12 from osteoblasts reduces early lymphoid progeni-
tors—a fraction of which was shown to localize at the
endosteum—without affecting HSCs or myeloerythroid
progenitors, suggesting a function of the so-called
osteoblastic niche in regulating early lymphopoiesis [16].
Depletion of osteocalcin-expressing bone cells (mature
osteoblasts and osteocytes), or deletion of the Notch ligand
DLL4 from the same cells, impairs the production of
T-lineage-competent lymphoid progenitors in the bone
marrow, resulting in decreased T-cell generation in the
thymus [31].
Regulation of the HSC niche by the mature
hematopoietic progeny
Recent work has highlighted the influence of different
mature hematopoietic cell subsets on the regulation of the
HSC niche. Among mature bone marrow cells, the greatest
body of evidence implicates monocytes/macrophages as
potential HSC regulators, usually indirectly through inter-
actions with other components of the niche [32–36].
Different studies have highlighted a role of mono-
cytes/macrophages in HSPC mobilization through
regulation of osteoblastic cells. G-CSF was shown to
deplete bone marrow monocytic cells, including endosteal
macrophages (osteomacs). In vivo depletion of macro-
phages caused loss of osteoblasts and mobilization of
HSPCs. Notably, expression of G-CSF receptor in mono-
cytic cells was sufficient to induce HSPC mobilization,
osteoblast suppression and Cxcl12 downregulation, sug-
gesting that G-CSF signaling in macrophages represses
some osteoblast-supporting factors [33, 36]. A population
of CD169? macrophages was shown to promote HSPC
retention in the bone marrow. Experimental depletion of
macrophages enhances physiological or enforced HSPC
mobilization, associated with a decrease in Cxcl12 levels
and downregulation of HSC maintenance genes in nestin?
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cells (but not in osteoblasts) [34]. In addition, CD169?
macrophages were implicated in regulating erythropoiesis
by mediating erythroblast retention in the bone marrow.
Although dispensable under homeostasis, macrophages
were required for a proficient erythropoietic stress
response, an effect mediated by VCAM1 expression by
macrophages [35]. A different study identified a population
of a-SMA? activated monocytes and macrophages that
localized adjacent to HSPCs and contributed to protect
HSPC from exhaustion under stress [32]. Again, the effect
was partially dependent on regulation of Cxcl12 expression
by stromal cells, although macrophages were also proposed
to directly protect HSCs from oxidative damage by PGE2
production.
On the other hand, the influence of osteoclasts—which
also differentiate from the monocyte/macrophage lin-
eage—on HSCs through bone remodeling has remained
controversial; different studies have reported that osteo-
clasts are either necessary, dispensable or even inhibitory
for HSC maintenance and mobilization. Thus, some studies
have suggested that osteoclasts promote the formation of
BM niches [37]. Also, osteoclast inhibition with calcitonin
decreased homeostatic and G-CSF-enforced HPSC mobi-
lization [38], but their suppression by zoledronate actually
enhanced G-CSF mobilization of HSPCs [36]. However,
different strains of osteoclast-deficient (osteopetrotic) mice
had normal or increased HSPC mobilization [39]. Also, the
BM of osteoclast-deficient, osteopetrotic mice (oc/oc or
RANK knockout mice) contained normal HSC activity
[40].
It has been recently shown that HSCs frequently localize
in the vicinity of megakaryocytes, and ablation of
megakaryocytes leads to cell cycle entry of quiescent HSC,
suggesting that this cellular population contributes to
maintaining HSC quiescence. This interaction was reported
as being mediated by soluble factors such as TGF-b1,
Cxcl4 and CLEC-2-mediated thrombopoietin production
[41–44]. Megakaryocytes were also shown to participate in
HSC niche remodeling after radioablation. Irradiation
induces megakaryocyte migration to the endosteum medi-
ated by thrombopoietin and CD41, and PDGF-BB secreted
by megakaryocytes mediates osteoblast expansion. Stimu-
lation of megakaryocyte function by thrombopoietin
administration improves HSC engraftment after transplan-
tation [45].
Neutrophil clearance has been proposed as an additional
regulatory mechanism of the HSC niche [46]. Infiltration
and elimination of aged CD62LO CXCR4HI neutrophils in
the bone marrow was proposed to cause a reduction in the
size and function of the HSC niche by decreasing the
number of CXCL12-abundant reticular (CAR) cells and the
levels of Cxcl12, thus promoting the circadian egress of
HSPCs into circulation. However, circadian oscillations of
Cxcl12 expression, directly induced in bone marrow stro-
mal cells by oscillating sympathetic activity [47], might
also contribute to some of the observed changes. The
reported effects of neutrophils on the HSC niche were
ultimately mediated by bone marrow macrophages—which
attract and phagocytose aged neutrophils—and required
activation of LXR in these cells.
Treg lymphocytes colocalize with HSCs near the endo-
steal surface in the bone marrow and contribute to
protecting transplanted allogeneic HSCs from immune
clearance, suggesting that the niche does not only nurture
HSCs but also provides them with immune privilege [48].
The malignant niche: a few knowns and many
unknowns
Although it has long been recognized that leukemia/lym-
phoma development is associated with an abnormal tissue
microenvironment in the affected organs, only in recent
years has experimental work begun to dissect specific roles
of the HSC niche in leukemogenesis (Fig. 1 right;
Table 1). Progress in this direction so far has lagged behind
the gradual understanding of the physiological HSC niche
and shared similar technical limitations. On one hand there
are uncertainties derived from the incomplete specificity,
efficiency and characterization of genetic drivers used to
target stromal cell populations (reviewed in [19]). These
problems add to the intrinsic limitations of murine cancer
models, e.g., how faithfully they recapitulate the human
diseases (regarding both their hematopoietic and microen-
vironmental abnormalities) or how much the experimental
procedure itself perturbs the niche (particularly in assays
where myeloconditioning is necessary, such as
xenotransplantation).
Two major ideas have emerged, supported by growing
evidence: (1) genetic alterations of the niche, rather than
the hematopoietic cell, may represent driving mutations
during malignant transformation; (2) cancer cells remodel
their niche into an abnormal environment that provides
preferential support of malignant cells—in detriment of
normal hematopoiesis—protects cancer cells from therapy-
induced cell death, and/or drives disease progression. From
these concepts immediately follows the idea that manipu-
lating the leukemic niche might represent an advantageous
therapeutic strategy, particularly in malignancies for which
targeting the hematopoietic cells has proven inefficient.
Niche abnormalities as potential initiating events
Initial studies showed that certain genetic alterations that
affected broadly the BM microenvironment also promoted
the development of abnormal hematopoiesis. Mice usually
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developed a myeloproliferative-like disease characterized
by hypergranulopoiesis, extramedullary hematopoiesis,
increased myeloid progenitors and eventually bone marrow
failure and anemia. These phenotypes were observed upon
deletion of retinoic acid receptor gamma (microenviron-
ment dependent) [49], deletion of retinoblastoma protein
(simultaneously required in microenvironment and myeloid
cells) [50], ubiquitous deletion of IkBa (non-hematopoietic
cell autonomous, but it is unclear whether the alteration in
the microenvironment was sufficient) [51], deletion of the
Notch ligand endocytosis regulator Mib1 (causing defec-
tive Notch activation in the microenvironment) [52] and
haploinsufficiency of Crebbp in the stromal cells [53].
These phenotypes were associated with histological chan-
ges in the BM, such as loss of trabecular bone [49, 50, 53]
or decreased number of adipocytes [52]. Among the
molecular pathways implicated in these processes were
increased TNFa/NFkB and aberrant Notch signaling. In
these studies—more extensively discussed in recent
reviews [54]—widespread deletion of the gene of interest
did not allow dissection of the cell population(s) responsi-
ble for the phenotype.
Subsequent studies refined this concept by modifying
specific stromal cell subsets. Specific deletion of the RNA
processing enzyme Dicer1 under the regulatory elements
of Osterix, a gene required for osteoblastic differentia-
tion—but not in mature osteoblasts, targeted by the
regulatory elements of Osteocalcin promoter—did not only
impair osteoblast differentiation, but was also found to
cause a myelodysplastic syndrome characterized by dys-
plastic morphology, lymphoid-deficient hematopoiesis and
increased HSPC proliferation and apoptosis. Key aspects of
the phenotype were recapitulated by specific Osterix-cre-
mediated deletion of Sbds, a Dicer-regulated gene that is
mutated in some leukemias [55]. However, it should be
noted that, although Osterix was originally reported to label
only cells committed to become osteoblasts [56], a much
wider recombination has been observed more recently after
the development of stronger reporter lines [57–59] (see
[19] for a review). Therefore, some of these phenotypes
might be derived from gene excision in other cells, besides
osteoprogenitors.
VEGF overexpression in Col2.3-cre? osteochon-
droprogenitors and their progeny constitutively activated
b-catenin and caused hematological abnormalities, extra-
medullary hematopoiesis and HSPC mobilization, likely
related to the dramatic bone mass increase and the aberrant
vascularization [60]. More dramatically, direct expression
of a constitutively active b-catenin form in osteoblasts
(Ctnnb1CAosb) impaired the differentiation of hematopoi-
etic progenitors and caused accumulation of immature
myeloid cells and dysplastic neutrophils in hematopoietic
tissues, resembling acute myeloid leukemia (AML). These
changes were caused by expression of jagged1 in osteo-
blasts and consequent excessive Notch signaling in HSPCs
[61].
These studies demonstrated that genetic alterations in
the microenvironment can trigger a pre-leukemic condition
(analogous to an oncogenic ‘‘first hit’’), but at the same
time suggested that additional mutations are required in the
hematopoietic cells to induce malignancy and/or overt
leukemia. Evidence of malignant transformation was lim-
ited in most studies. In the case of Dicer1-deleted mice,
rare sporadic occurrences of AML that exhibited cytoge-
netic alterations were reported [55]. Most remarkably,
frequent recurrent chromosomal alterations and somatic
mutations were detected in Ctnnb1CAosb mice, including
those in an ortholog region of human chromosome 7q,
which is altered in AML and myelodysplastic syndromes.
Notably, transformed HSCs from Ctnnb1CAosb mice
became autonomous and could transfer the AML to WT
recipients [61].
In spite of these experimental models providing a proof
of concept, we are still lacking direct demonstration that an
initial lesion in the microenvironment may play a causative
role in human leukemias. However, the situation is some-
what reminiscent of that traditionally observed in
extraganglionar lymphomas associated with local infec-
tious processes (such as Helicobacter pylori in MALT
lymphomas) in which the pathogen may provide antigenic
stimulation to malignant B-cells and the tumor remits after
eradication of the infection [62]. In leukemias, available
evidence is only indirect. Decreased expression of DICER,
DROSHA and SBDS was detected in MSCs—but not in
leukocytes—from MDS patients compared to healthy
individuals [63]. SBDS is inactivated by mutations in the
human Shwachman–Bodian–Diamond syndrome, featuring
skeletal abnormalities, bone marrow failure and suscepti-
bility to developing myelodysplastic syndrome and
secondary AML [55]. CREBPP heterozygosity in humans
causes the Rubinstein–Taybi syndrome, characterized by
skeletal defects and cancer predisposition, including leu-
kemias [64]. Activation of b-catenin in osteoblasts,
accompanied by Notch activation in hematopoietic cells,
was detected in over one-third of patients with myelodys-
plastic syndrome or AML [61].
Malignant cells create aberrant niches
Knowledge of how leukemic cells interact with their
microenvironment has followed progress in the character-
ization of the normal HSC niche, and is affected by
similar—if more notorious—uncertainties.
Xenografted primary human AML stem cells (CD34?
CD38-) were reported to exhibit preferential homing and
engraftment to the endosteal, osteoblast-rich area of the
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BM [65], while acute lymphoblastic leukemia (ALL) cells
tended to localize to vascular regions expressing E-selectin
and Cxcl12, overlapping with perivascular HSPC niches
[66, 67]; however, it was later recognized that these
endothelial microdomains were juxtaposed to the endos-
teum [68], suggesting similar primary homing location of
AML/ALL cells. Endosteal human leukemia stem cells
(LSCs) causing AML were reported as characteristically
quiescent and chemoresistant; cell cycle entry induced by
G-CSF enhanced chemotherapy-induced apoptosis and
elimination of LSCs [65, 69].
Xenotransplantation of ALL cell lines has been shown
to disrupt the normal bone marrow microenvironment
[66, 68]. Particularly, these cells can cause severe damage
of the vasculature and endosteum-lining cells and lead to
the formation of abnormal niches primarily formed by the
mutated cells, which highly express stem cell factor but
produce low levels of Cxcl12. In these aberrant niches,
both the numbers and the traffic of normal HSPCs were
reduced. This was proposed as a mechanism by which
normal hematopoiesis could be impaired even in the
presence of a low tumor burden. In the same xenotransplant
model, chemotherapy was shown to induce the formation
of transient niches consisting of small foci of surviving
ALL cells and nestin? LepR? NG2? stromal cells with
properties of MSCs (multipotent sphere formation, in vitro
differentiation). Formation of these structures required
CCL3 and TGFb1 produced by ALL cells and, in spite of
their short life, were proposed to protect ALL cells from
chemotherapy-induced apoptosis. A recent study has
shown that T-ALL cells require Cxcl12-producing
endothelial cells, and CXCR4 antagonism suppressed
T-ALL in primary xenografts [70].
It has been recently shown that MSCs exhibit an altered
gene expression program in myelodysplastic syndromes,
with increased expression of genes associated with osteo-
progenitor cell fate, inflammation and fibrosis. These
MSCs are capable of promoting the engraftment or prop-
agation of myelodysplasia in orthotopic xenografts [71].
Severe osteoblastic defects were found in a model of
myeloid blast-crisis chronic myeloid leukemia (CML, dri-
ven by BCR-ABL;Nup98/HoxA9), with decreased
osteoprogenitors, endosteal-lining osteoblasts and bone
mass, associated with increased CCL3 expression [72].
Using a mouse model of chronic-phase, BCR-ABL-in-
duced CML (SCL-tTA;TRE-BCR/ABL mice), two studies
have provided evidence for the concept that leukemic cells
can remodel the bone marrow environment into a self-
supporting niche that impairs normal hematopoiesis. Leu-
kemic cells were shown to stimulate excessive production
of osteoblastic cells. These cells had reduced expression of
HSC maintenance factors and impaired ability to support
normal HSCs, while having limited impact on LSCs.
Abnormal osteoblastic cells overexpressed inflammation-
and myelofibrosis-related genes, contributed to bone mar-
row fibrosis, and their expansion was driven by TPO,
CCL3 and direct contact with leukemic cells [73]. In
another study, G-CSF overproduction by CML cells
reduced Cxcl12 expression by bone marrow stromal cells
and increased several pro-inflammatory cytokines, leading
to selective impairment of normal HSCs that also favored
the growth of CML stem cells [74]. Pro-inflammatory
cytokines produced by mature leukemic cells had also
direct effects on the leukemic HSPC; thus, BCR-ABL-de-
pendent secretion of IL-6 by CML cells drives myeloid
differentiation of leukemic multipotent MPP, establishing a
feed-forward loop [75].
Recent work from our laboratory has demonstrated that
the manifestation of JAK2V617F-induced myeloproliferative
neoplasms (MPN) requires the loss of sympathetic regu-
lation in the HSC niche [76]. Sympathetic fibers and
associated Schwann cells are consistently decreased in the
bone marrow of JAK2V617F-positive MPN patients and
mice due to apoptosis induced by MPN cell-derived IL-1b.
In turn, neuroglial damage compromises the survival of
nestin? cells, which are also reduced in number over the
course of the disease. This loss of MSCs plays a driving
role in MPN development, since selective depletion of
nestin? cells, or Cxcl12 produced by them, is sufficient to
accelerate disease progression. Conversely, pharmacologi-
cal compensation of neural damage blocks MPN
progression (see below).
The leukemic niche as a therapeutic target
Growing evidence of the active participation of the HSC
niche in hematological malignancies, either by providing
an initiating lesion or by responding to leukemia-induced
remodeling, suggests that its therapeutic targeting may
have therapeutic benefit. This could be potentially achieved
through inhibition of essential interactions between LSCs
and supporting cells, or by reversion of niche-related
changes that drive the course of the disease. We have
provided direct evidence of the latter in the context of
JAK2V617F-induced MPN, in which loss of nestin? MSCs
caused by neuroglial damage promotes disease progression
[76]. Rescue of the defective sympathetic stimulation by
chronic administration of b3-adrenergic agonists prevented
the loss of nestin? MSC and inhibited disease progression
at both early and late stages, preventing neutrophilia,
thrombocytosis, IL-1b production, bone marrow fibrosis
and expansion of LSCs, while having negligible effects on
normal HSCs. Similarly, treatment of MPN-affected mice
with the neuroprotective molecule 4-methylcatecol, which
protects sympathetic fibers and Schwann cells, abolished
MPN-related neutrophilia. These results demonstrate that
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specific reversion of malignancy-induced changes in the
bone marrow microenvironment may be sufficient to block
MPN. They also prove that niche transformation represents
a major driving force and a requirement for disease pro-
gression, and provide a novel, potential safe therapeutic
approach where hematopoietic cell-directed therapies have
previously shown limited efficacy.
However, this is very unlikely the case of more
aggressive leukemias, such as AML, despite some simi-
larities shown in a recent study suggesting that sympathetic
neuropathy caused by acute myeloid leukemic cells pro-
motes malignancy in an altered hematopoietic stem cell
niche [77]. Unlike in MPN [76], adrenergic drugs did not
significantly impact AML progression in this study. How-
ever, emerging evidence suggests that the
microenvironment might represent a feasible therapeutic
target for AML. For instance, inhibition of Cxcr4/Cxcl12
signaling may show some therapeutic advantage in AML.
Cxcr4 antagonists (AML3100/Plerixafor and the novel
LY2510924) induce leukemic cell mobilization and
enhance the antileukemic action of chemotherapy in
xenotransplant models [78, 79]. Furthermore, addition of
AMD3100 to cytotoxic chemotherapy increased remission
rates in patients with relapsed or refractory AML in a phase
1/2 clinical study [80].
Considerations for the future
As outlined at the beginning of this review, elucidation of
the cellular and molecular interactions in the HSC niche
has two major practical motivations. One is the identifi-
cation of key molecules that would allow the production,
maintenance and expansion of HSCs. Identification of the
specific factors that contribute to maintaining stemness
in vivo would facilitate the development of chemically
defined culture media, avoiding the use of animal-derived
culture supplements and possibly the need for time-con-
suming coculture protocols. The identification of specific
microenvironments and factors required for the mainte-
nance of different types of hematopoietic progenitors could
make possible the selective ex vivo generation of different
lineages for specific applications.
Another aspect with translational potential is the iden-
tification of alterations in the bone marrow niche directly
associated with, and required for, the development of each
type of leukemia. It is expected that different malignancies
will induce a specific set of abnormalities and will also
differ in their dependence on the niche. Thus, it would not
be surprising to find that aggressive, acute leukemias with
accumulated mutations may become relatively cell auton-
omous and less sensitive to microenvironmental regulation.
Most relevant will be to identify cellular processes or
pathways selectively required for the maintenance of
malignant progenitors—as opposed to normal HSCs—and
susceptible to pharmacological targeting. The success of
niche-directed therapies will likely depend on how accu-
rately we can validate preclinical findings from mouse
models in the human system, for which it will be critical to
develop parallel sets of molecular markers for human
HSCs and niche cells, as well as more faithful xenotrans-
plant models.
From the more theoretical point of view, research in the
immediate future is expected to refine our knowledge of the
composition of the HSC niche, dissecting between direct
interactions with bona fide ‘‘niche cells’’ and indirect signals
from more distant components. It would also be advanta-
geous to clarify some of the confusion in the field resulting
from the use of incompletely characterized genetic drivers
and partially overlapping markers (reviewed in [19]). Again,
it is also expected that improved xenograft models and
human cell markers will allow a more direct investigation of
the biology of the human HSC niche.
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